MREO Mereo Biopharma Group Plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MREO

Price (delayed)

$0.318

Market cap

$50.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.25

Enterprise value

$14.54M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 25

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, ...

Highlights
Mereo Biopharma Group's debt has shrunk by 100% QoQ and by 100% YoY
The EPS has grown by 29% YoY
The equity has declined by 43% year-on-year and by 17% since the previous quarter
The quick ratio has contracted by 39% from the previous quarter and by 30% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mereobiopharma.com
Peers: NTLA ALLO CRSP EDIT

Key stats

What are the main financial stats of MREO

MREO stock price

How has the Mereo Biopharma Group stock price performed over time
Intraday
-4.85%
1 week
-7.83%
1 month
10.76%
1 year
-87.53%
YTD
-23.69%
QTD
-3.64%

Financial performance

How have Mereo Biopharma Group's revenue and profit performed over time
Revenue
$500,000
Gross profit
$368,000
Operating income
-$37.97M
Net income
-$35.71M
Gross margin
73.6%
Net margin
-7,142%
The net income has increased by 24% year-on-year and by 15% since the previous quarter
The operating income has grown by 22% YoY and by 6% from the previous quarter
Mereo Biopharma Group's net margin has increased by 15% QoQ
Mereo Biopharma Group's operating margin has increased by 6% QoQ

Price vs fundamentals

How does MREO's price correlate with its fundamentals

Growth

What is Mereo Biopharma Group's growth rate over time

Valuation

What is Mereo Biopharma Group stock price valuation
P/E
N/A
P/B
1.49
P/S
101.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.07
The EPS has grown by 29% YoY
The P/B is 65% lower than the last 4 quarters average of 4.5
The equity has declined by 43% year-on-year and by 17% since the previous quarter
MREO's P/S is 76% below its last 4 quarters average of 441.1

Efficiency

How efficient is Mereo Biopharma Group business performance
MREO's ROA is down by 23% YoY but it is up by 3.2% QoQ
The return on equity has declined by 17% year-on-year but it has grown by 2% since the previous quarter
The ROS has grown by 14% from the previous quarter

Dividends

What is MREO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MREO.

Financial health

How did Mereo Biopharma Group financials performed over time
MREO's total assets is down by 41% year-on-year and by 12% since the previous quarter
The quick ratio has contracted by 39% from the previous quarter and by 30% YoY
Mereo Biopharma Group's debt is 100% lower than its equity
Mereo Biopharma Group's debt to equity has shrunk by 100% YoY
Mereo Biopharma Group's debt has shrunk by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.